Guangxi Wuzhou Zhongheng Group (600252.SH) issued an announcement, based on the National Chinese Patent Medicine Joint Procurement Office in January 2024...
According to a notice from Guangxi Wuzhou Zhongheng Group (600252.SH), the company announced that the proposed selection results for centralized procurement released by the National Chinese Patent Medicine Alliance Procurement Office on December 30, 2024, on the Hubei medical insurance service platform indicate that its subsidiary Wuzhou Pharmaceutical's Thrombin Injection (lyophilized) is expected to win the bid in this centralized procurement.
Wuzhou Pharmaceutical's Thrombin Injection (lyophilized) (specification 150mg/vial), which is expected to be selected for the National Chinese Patent Medicine Procurement Alliance centralized procurement, had a total sales revenue of 0.67 billion yuan for the year 2023, accounting for 21.63% of the company's revenue of 3.097 billion yuan in 2023.